Optix Eye Care has been invited to participate in the
exclusive, initial release of a new, at-home vision monitoring service,
continuing their commitment to incorporating the newest technology in the
prevention and treatment of ocular disease. The mVT® Service is an accurate, portable, and
user-friendly system that enables patients with retinal disease to monitor
vision function at home.
The mVT® Service, developed by Vital Art and Science, LLC,
is the first patented, clinically validated, and FDA cleared Ophthalmic medical
device, and is available on the Apple App Store for all patients diagnosed with
or concerned about maculopathy. The mVT® Service was developed for use by patients who are at risk and/or who have
a family history of Diabetic Retinopathy, Dry AMD, and Wet AMD.
Patients prescribed the mVT® Service, which includes the
mVT® App, log-in twice a week and perform a short, four-to-six minute, shape
discrimination exercise. Patients are shown a series of circles and they select
the one that appears different to them. After each selection they are shown
another series of circles, and each time the differences in the shapes become
more subtle. This exercise effectively tracks changes in vision related to
retinal disease. If there are significant changes, the prescribing doctor is
alerted, allowing them to contact the patient to come in sooner for an
assessment and possibly treatment.
The service is currently available for iOS devices and is in
development for Droid and Windows devices. Per FDA regulations, the service
does require a prescription from the patient’s Optometrist or Ophthalmologist
and is not intended as a diagnostic tool or a treatment. Optix Eye Care will
still require annual comprehensive eye exams and follow-up testing for patients
participating in the mVT® Service.
For more information on the mVT® Service, visit www.myvisiontrack.com
No comments:
Post a Comment